Mazdutide vs Survodutide
Mazdutide and survodutide are distinct GLP-1/glucagon dual agonists, each with published phase 3 weight trials. Their trials differ in population and estimand; Innovent reports specified mazdutide approvals in China, while no FDA approval was verified for either agent.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Mazdutide
Dossier overview
Survodutide
Dossier overview
What the evidence actually compares
Both mazdutide and survodutide activate GLP-1 and glucagon receptors, but they are distinct molecules with separate dosing regimens and trial programs. Shared targets do not imply interchangeable efficacy or safety.
The published SYNCHRONIZE-1 phase 3 trial studied survodutide versus placebo in adults with obesity or overweight and a complication, excluding diabetes. Its week-76 weight results used a treatment-regimen estimand. A separate SYNCHRONIZE-MASLD study measured liver-fat and weight outcomes; MRI liver-fat changes are not biopsy-proven steatohepatitis resolution. SYNCHRONIZE-1, PMID 42253238 · SYNCHRONIZE-MASLD, PMID 42252333
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | Survodutide | Mazdutide |
|---|---|---|
| Mechanism | Both mazdutide and survodutide activate GLP-1 and glucagon receptors, but they are distinct molecules with separate dosing regimens and trial programs. Shared targets do not imply interchangeable efficacy or safety. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | Published phase 3 SYNCHRONIZE-1 study | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited Survodutide sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
Mazdutide GLORY-2 enrolled Chinese adults with obesity, including some with type 2 diabetes; SYNCHRONIZE-1 excluded diabetes and had different follow-up and estimand. Their placebo-controlled results cannot establish which dual agonist is superior. No cited randomized head-to-head trial resolves that question.
Survodutide remained investigational in the reviewed sources; no FDA approval for either agent was verified. Innovent separately reports Chinese approvals of mazdutide for specified adult uses. The source for the Survodutide evidence above is this primary record; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.